Proportion using one or more medications at one year after surgery Number of participants · patients with eyes with cataract and glaucoma
Combined surgery may leads to lower proportion using one or more medications at one year after surgery… compared with phacoemulsification alone (low certainty).
1 finding from 1 review
Proportion of participants who required further glaucoma surgery, including laser · people with cataracts and open angle glaucoma, many of whom had mild or moderate glaucoma, which was well‐controlled with medication
Cataract surgery with Hydrus microstent may leads to lower proportion of participants who required further glaucoma surgery,… compared with cataract surgery alone (low certainty).
1 finding from 1 review
All‐cause mortality within 30 days of surgery · people with a low platelet count
It is very uncertain whether prophylactic platelet transfusion prior to surgery changes all‐cause mortality within 30 days of surgery compared with no prophylactic platelet transfusion prior to surgery (very low certainty).
1 finding from 1 review
Mortality secondary to bleeding within 30 days of surgery – not reported · people with a low platelet count
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality secondary to thromboembolism within 30 days of surgery – not reported · people with a low platelet count
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality secondary to infection within 30 days of surgery – not reported · people with a low platelet count
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with major bleeding within 7 days of surgery (surgical site bleeding requiring a second intervention or reoperation or surgical site bleeding that causes a haematoma or haemarthrosis of sufficient size to delay mobilisation ... · people with a low platelet count
It is very uncertain whether prophylactic platelet transfusion prior to surgery changes number of participants with major bleeding within 7 days of surgery… compared with no prophylactic platelet transfusion prior to surgery (very low certainty).
1 finding from 1 review
Number of participants with minor procedure‐related bleeding within 7 days of surgery · people with a low platelet count
It is very uncertain whether prophylactic platelet transfusion prior to surgery changes the number of participants with minor procedure‐related bleeding… compared with no prophylactic platelet transfusion prior to surgery (very low certainty).
1 finding from 1 review
Serious adverse events (surgery‐related adverse effects within 30 days) · people with a low platelet count
1 finding from 1 review
Short term mortality · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Serious adverse events · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes serious adverse events compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Quality of life · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes quality of life compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Pain · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Return to normal activities (days) · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Patient readmissions · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes number of hospital readmissions compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Failed discharge · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes failed discharge compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ stoma formation (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ stoma… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ bowel resection (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ bowel… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related postoperative mortality (28 days to 6 months of surgery4) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).
1 finding from 1 review